acomplia aventis rimonabant sanofi - for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. many experimental paradigms of neurological disease. rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two In the UK, it has been available since the end of July 2006. As of 2007, the drug was available in 38 countries. clinical studies. Reports of severe depression are frequent. This is deemed to result from the drug being active in the central nervous system, an area of human physiology that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval.[2] Rimonabant may also be found to be effective in assisting some smokers to quit smoking. Sanofi-Aventis is currently conducting studies to determine the possible value of Finland and Norway. It is expected in Belgium[3] and Sweden in 2007. Ordinary obesity will, according to official medical recommendations, not be enough to acquire the prescription in Sweden; there are additional requirements concerning abnormal blood lipid levels.[4] and other related side effects associated with use of the drug. Shortly after market introduction, press reports and independent studies suggest that side effects occur stronger and more commonly than shown by the manufacturer in their Subsequently, Sanofi-Aventis announced that it projects that the drug will be sold shortly thereafter in Denmark, Ireland, Germany, Rimonabant (also known as SR141716, Acomplia, Riobant, Slimona, Rimoslim, and Zimulti)[1] is an anorectic anti-obesity drug. It is a CB1 cannabinoid receptor antagonist. suggest that rimonabant is effective for both uses. However, the FDA has explicitly stated to Sanofi-Aventis that without additional studies rimonabant cannot be approved in On 21 June 2006, the European Commission approved the sale of rimonabant in the then 25-member European Union. Sanofi.
The EU's approval was not a blanket approval, nor did it approve Acomplia for non-obesity related problems such as smoking cessation, although off-label use of the drug. the United States in 2006.[citations needed] The French pharma firm Sanofi-Aventis disclosed that a complete response to the FDA's approvable letter was submitted on October rimonabant in smoking-cessation therapy. The Studies with Rimonabant and Tobacco Use (STRATUS) Program involves more than 6,000 subjects. STRATUS is designed to explore two that the French manufacturer Sanofi-Aventis failed to demonstrate the safety of rimonabant and voted against recommending the anti-obesity treatment for approval.[2] Despite the FDA issuing an approvable letter in February 2006 for the obesity indication and a non-approvable letter for smoking cessation, the drug did not enter the market for patients with a body mass index greater than 30 kg/m², or patients wih a BMI greater than 27 kg/m² with associated risk factors, such as type 2 diabetes or dyslipidaemia. still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia. still possible. The approval is in combination with diet and exercise for the treatment of obese patients (BMI greater than 27) with associated risk factors, such as type 2 diabetes or dyslipidaemia. still possible. The approval is in combination with diet and exercise for the treatment of obese
acomplia aventis rimonabant sanofi
acomplia aventis rimonabant sanofi Powered by:
acomplia aventis rimonabant sanofi
Related Websites:
Order Generics on www.generic-pharmacy.net
Buy Generic Zoloft | Buy Generic Zocor |